Is there an association between lymph node size and hyperprogression in immunotherapy-treated patients?

1YU EM., LINVILLE L., ROSENTHAL M., ARAGON-CHING JB. A contemporary review of immune checkpoint inhibitors in advanced clear cell renal cell carcinoma. Vaccines. 2021, 9:919.Search in Google Scholar

2BARATA PC., RINI BI. Treatment of renal cell carcinoma: current status and future directions. Ca-Cancer J Clin. 2017, 67:507-24.Search in Google Scholar

3DÍAZ-MONTERO C., RINI B. The immunology of renal cell carcinoma. Nat Rev Nephrol. 2020, 16:721-35.Search in Google Scholar

4HSIEH JJ., PURDUE MP., SIGNORETTI S., SWANTON C., ALBIGES L., SCHMIDINGER M., et al. Renal cell carcinoma. Nat Rev Dis Primers. 2017, 3:17009.Search in Google Scholar

5JENKINS RW., BARBIE DA., FLAHERTY KT. Mechanisms of resistance to immune checkpoint inhibitors. Br J Cancer. 2018, 118:9-16.Search in Google Scholar

6MARIN-ACEVEDO JA., KIMBROUGH EO., LOU Y. Mechanisms of resistance to immune checkpoint inhibitors. J Hematol Oncol. 2021, 14:1-29.Search in Google Scholar

7HARGADON KM., JOHNSON CE., WILLIAMS CJ: Immune checkpoint blockade therapy for cancer. an overview of fda-approved immune checkpoint inhibitors. Int Immunopharmacol. 2018, 62:29-39.Search in Google Scholar

8SHIRAVAND Y., KHODADADI F., KASHANI SMA., HOSSEINI-FARD SR., HOSSEINI S., SADEGHIRAD H., et al. Immune checkpoint inhibitors in cancer therapy. Curr Oncol. 2022, 29:3044-60.Search in Google Scholar

9LIU X., QIAO L. Hyperprogressive disease in malignant carcinoma with immune checkpoint inhibitor use: a review. Front Nutr. 2022, 9:810472.Search in Google Scholar

10ZHAO Z., BIAN J., ZHANG J., ZHANG T., LU X. Hyperprogressive disease in patients suffering from solid malignancies treated by immune checkpoint inhibitors: a systematic review and meta-analysis. Front Oncol. 2022, 12:843707.Search in Google Scholar

11HAN XJ., ALU A., XIAO YN., WEI YQ., WEI XW. Hyperprogression: a novel response pattern under immunotherapy. Clin Transl Med.. 2020, 10:e167.Search in Google Scholar

12WANG X., WANG F., ZHONG M., YARDEN Y., FU L. The biomarkers of hyperprogressive disease in pd-1/pd-L1 blockage therapy. Mol Cancer. 2020, 19:81.Search in Google Scholar

13DENIS M., DURUISSEAUX M., BREVET M., DUMONTET C. How can immune checkpoint inhibitors cause hyperprogression in solid tumors? Front Immunol. 2020, 11:492.Search in Google Scholar

14PATEL K., MUKHI H., PATEL A., MEHTA D., CLINTON N., BROWN B., et al. Differentiating pseudoprogression from hyperprogression in patients treated with immunotherapies. Targeted Ther Oncol. 2022, 11:16.Search in Google Scholar

15ARASANZ H., ZUAZO M., BOCANEGRA A., CHOCARRO L., BLANCO E., MARTÍNEZ M., et al. Hyperprogressive disease: main features and key controversies. Int J Mol Sci. 2021, 22:3736.Search in Google Scholar

16PARK HJ., KIM KW., WON SE., YOON S., CHAE YK., TIRUMANI SH., et al. Definition, incidence, and challenges for assessment of hyperprogressive disease during cancer treatment with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Netw Open. 2021, 4:e211136.Search in Google Scholar

17CHAMPIAT S., DERCLE L., AMMARI S., MASSARD C., HOLLEBECQUE A., POSTEL-VINAY S., et al. Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1. Clin Cancer Res. 2017, 23:1920-8.Search in Google Scholar

18FERRARA R., MEZQUITA L., TEXIER M., LAHMAR J., AUDIGIER-VALETTE C., TESSONNIER L., et al. Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy. JAMA Oncol. 2018, 4:1543-52.Search in Google Scholar

19KATO S., GOODMAN A., WALAVALKAR V., BARKAUSKAS DA., SHARABI A., KURZROCK R. Hyperprogressors after Immunotherapy: analysis of genomic alterations associated with accelerated growth rate. Clin Cancer Res. 2017, 23:4242-50.Search in Google Scholar

20ADASHEK JJ., KATO S., FERRARA R., LO RUSSO G., KURZROCK R. Hyperprogression and immune checkpoint inhibitors: hype or progress? Oncologist. 2020, 25:94-8.Search in Google Scholar

21MATOS I., MARTIN-LIBERAL J., GARCÍA-RUIZ A., HIERRO C., OCHOA DE OLZA M., VIAPLANA C., et al. Capturing hyperprogressive disease with immune-checkpoint inhibitors using recist 1.1 criteria.. Clin Cancer Res. 2020, 26:1846-55.Search in Google Scholar

22KAS B., TALBOT H., FERRARA R., RICHARD C., LAMARQUE JP., PITRE-CHAMPAGNAT S., et al. Clarification of definitions of hyperprogressive disease during immunotherapy for non-small cell lung cancer. JAMA oncol. 2020, 6:1039-46.Search in Google Scholar

23JIA W., GAO Q., HAN A., ZHU H., YU J. The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy. Cancer Biol Med. 2019, 16:655.Search in Google Scholar

24MA Y., WANG Q., DONG Q., ZHAN L., ZHANG J. How to differentiate pseudoprogression from true progression in cancer patients treated with immunotherapy. Am J Cancer Res. 2019, 9:1546-53.Search in Google Scholar

25WANG Y., WANG M., WU HX., XU RH. Advancing to the era of cancer immunotherapy. Cancer Commun (Lond). 2021, 9:803-29.Search in Google Scholar

26LIN M., VANNESTE B., YU Q., CHEN Z., PENG J., CAI X. Hyperprogression under immunotherapy: a new form of immunotherapy response?—a narrative literature review. Transl Lung Cancer. 2021, 10:3276-91.Search in Google Scholar

27KOCIKOWSKI M., DZIUBEK K., PARYS M. Hyperprogression under immune checkpoint-based immunotherapy–current understanding, the role of pd-1/pd-l1 tumour-intrinsic signalling, future directions and a potential large animal model. Cancers. 2020, 12:804.Search in Google Scholar

28KROEGER N., PANTUCK AJ., CONNOR WELLS JC. Characterizing the impact of lymph node metastases on the survival outcome for metastatic renal cell carcinoma patients treated with targeted therapies. Eur Urol. 2015, 68:506-15.Search in Google Scholar

29STARES M., CHAUHAN V., MOUDGIL-JOSHI J. Initial active surveillance for patients with metastatic renal cell carcinoma: 10 years experience at a regional cancer Centre. Cancer Med.. 2022, 12:5255-64.Search in Google Scholar

30LI C., JIANG P., WEI S., XU X., WANG J. Regulatory t cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects. Molecular cancer. 2020, 19:1-23.Search in Google Scholar

31WEI Z., ZHANG Y. Immune cells in hyperprogressive disease under immune checkpoint-based immunotherapy. Cells. 2022, 11:1758.Search in Google Scholar

32HAN J., DONG L., WU M., MA F. Dynamic polarization of tumor-associated macrophages and their interaction with intratumoral t cells in an inflamed tumor microenvironment: from mechanistic insights to therapeutic opportunities.. Front Immunol. 2023, 14:2246.Search in Google Scholar

33TAY C., QIAN Y., SAKAGUCHI S. Hyper-progressive disease: the potential role and consequences of t-regulatory cells foiling anti-pd-1 cancer immunotherapy. Cancers (Basel). 2020, 12:48.Search in Google Scholar

34OHUE Y., NISHIKAWA H. Regulatory t (treg) cells in cancer: can treg cells be a new therapeutic target? Cancer Sci. 2019, 110:2080-9.Search in Google Scholar

35FENG Y., YE Z., SONG F., HE Y., LIU J. The role of tams in tumor microenvironment and new research progress. Stem Cells Int. 2022, 2022:5775696.Search in Google Scholar

36TOKI MI., SYRIGOS N., SYRIGOS K. Hyperprogressive disease: a distinct pattern of progression to immune checkpoint inhibitors. Int J Cancer. 2020, 149:277-86.Search in Google Scholar

37ZAREBA P., PINTHUS JH., RUSSO P. The contemporary role of lymph node dissection in the management of renal cell carcinoma.. Ther Adv Urol. 2018, 10:335-42.Search in Google Scholar

38SUN JX., LIU CQ., ZHANG ZB. A novel predictive model of pathological lymph node metastasis constructed with preoperative independent predictors in patients with renal cell carcinoma. J Clin Med. 2023, 12:441.Search in Google Scholar